Published in Surgery Litigation and Law Weekly, August 4th, 2006
Study 1: A researcher reviews the treatment and pharmacologic management of benign prostatic hyperplasia in the context of common comorbidities in a recent issue of the American Journal of Managed Care.
According to the review, "Benign prostatic hyperplasia (BPH) is extremely common in the aging man and may cause significant lower urinary tract symptoms (LUTS) necessitating treatment. Drug treatment is the mainstay of treatment for symptomatic BPH and is directed at relaxing prostatic smooth muscle, reducing prostate volume, or a combination of these effects....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Surgery Litigation and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.